3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Retinoblastoma
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Mouth Neoplasms
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
Observation
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled